EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Current Real‐World Status of Off‐Label Under‐ and Over‐Dose of Direct Oral Anticoagulants After Atrial Fibrillation Ablation

Tabito Kino iD, Akihiko Nogami, Kyoko Soejima, Kikuya Uno, Koichiro Kumagai iD, Takashi Kurita, Masayuki Fukuzawa, Atsushi Takita, Tomoko Ishizu, Kazutaka Aonuma, RYOUMA Registry Investigators

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16560 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Tabito Kino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Off-Label Use, Catheter Ablation, Factor Xa Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by Daiichi Sankyo, Co. Ltd., Tokyo, Japan..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Off‐label under‐ and overdosing of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is not uncommon in real‐world practice.

Objective

This study aimed to identify efficacy and safety of off‐label DOACs dose after AF ablation.

Methods

The RYOUMA registry was a prospective multicenter study of Japanese patients who underwent AF ablation between 2017 and 2018. DOAC prescriptions were categorized into on‐label standard dose, on‐label reduced dose, off‐label underdose, and off‐label overdose.

Results

The proportion of off‐label doses among patients after AF ablation varied depending on the type of DOAC, ranging from 13.5% to 34.9%. Of 2821 patients, 366 (13.0%) were prescribed an off‐label underdose and exhibited significantly higher CHADS 2 , CHA 2 DS 2 ‐VASc, CHA 2 DS 2 ‐VA, HELT‐E 2 S 2 , and HAS‐BLED scores, age, concomitant use of antiplatelets, and lower weight when compared to the on‐label standard dose ( n = 1809). While the incidence of ischemic stroke after 1 year of off‐label underdose was notably low (0.28%), the rate of major bleeding was relatively high (1.7%). Off‐label overdose was prescribed to 134 patients (4.8%), who showed a significantly higher incidence of major bleeding (3.0%) compared to on‐label standard dose (0.91%; p = 0.02). The off‐label overdose group did not have any particular background and its thromboembolic risk was, conversely, low. The most likely cause of off‐label overdose was clinicians potentially overlooking dose criteria, including advanced age, low body weight, and low creatinine clearance.

Conclusions

In patients after AF ablation, off‐label DOAC overdose was infrequent, but significantly associated with higher incidence of major bleeding during the remote period after AF ablation. Trial Registration The study was registered as UMIN000026092 (University Hospital Medical Information Network‐Clinical Trial Registry).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationOff-Label UseCatheter AblationFactor Xa InhibitorsStrokeHumansMaleFemaleAgedAdministration, OralMiddle AgedProspective StudiesRegistriesTreatment OutcomeJapanRisk FactorsTime FactorsRisk AssessmentHemorrhageIncidence

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationdirect oral anticoagulant therapyoff‐label overdoseoff‐label underdose

Substanzen

Factor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Cardiology, Kyorin University School of Medicine, Tokyo, Japan.
  • Heart Rhythm Center, Tokyo Heart Rhythm Hospital, Tokyo, Japan.
  • Heart Rhythm Center, Fukuoka Sanno Hospital, Fukuoka, Japan.
  • Division of Cardiovascular Center, Kindai University School of Medicine, Osaka, Japan.
  • Primary Medical Science Department, Daiichi Sankyo Co. Ltd., Chuo-ku, Japan.

ORCID-Profile: Tabito Kino, Koichiro Kumagai

Förderung

  • This study was supported by Daiichi Sankyo, Co. Ltd., Tokyo, Japan.

Zitieren

APA

Kino, T., Nogami, A., Soejima, K., Uno, K., Kumagai, K., Kurita, T., Fukuzawa, M., Takita, A., Ishizu, T., Aonuma, K., & RYOUMA Registry Investigators (2025). Current Real‐World Status of Off‐Label Under‐ and Over‐Dose of Direct Oral Anticoagulants After Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16560

Vancouver

Kino T, Nogami A, Soejima K, Uno K, Kumagai K, Kurita T, et al. Current Real‐World Status of Off‐Label Under‐ and Over‐Dose of Direct Oral Anticoagulants After Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16560

BibTeX
@article{Kino2025,
  author = {Kino, Tabito and Nogami, Akihiko and Soejima, Kyoko and Uno, Kikuya and Kumagai, Koichiro and Kurita, Takashi and Fukuzawa, Masayuki and Takita, Atsushi and Ishizu, Tomoko and Aonuma, Kazutaka and RYOUMA Registry Investigators, RYOUMA Registry Investigators},
  title = {Current Real‐World Status of Off‐Label Under‐ and Over‐Dose of Direct Oral Anticoagulants After Atrial Fibrillation Ablation},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16560}
}
Kostenlos starten →